Abstract
Data from prospective cohorts describing dyslipidaemia prevalence and treatment trends are lacking. Using data from the prospective CoLaus study, we aimed to examine changes in serum lipid levels, dyslipidaemia prevalence and management in a population-based sample of Swiss adults. Cardiovascular risk was assessed using PROCAM. Dyslipidaemia and low-density lipoprotein cholesterol (LDL-C) target levels were defined according to the Swiss Group for Lipids and Atherosclerosis. Complete baseline and follow up (FU) data were available for n = 4863 subjects during mean FU time of 5.6 years. Overall, 32.1% of participants were dyslipidaemic at baseline vs 46.3% at FU (p < 0.001). During this time, lipid lowering medication (LLM) rates among dyslipidaemic subjects increased from 34.0% to 39.2% (p < 0.001). In secondary prevention, LLM rates were 42.7% at baseline and 53.2% at FU (p = 0.004). In multivariate analysis, LLM use among dyslipidaemic subjects, between baseline and FU, was positively associated with personal history of CVD, older age, hypertension, higher BMI and diabetes, while negatively associated with higher educational level. Among treated subjects, LDL-C target achievement was positively associated with diabetes and ne...Continue Reading
References
Dec 17, 2005·The American Journal of Medicine·Leif R Erhardt
Mar 28, 2008·BMC Cardiovascular Disorders·Mathieu FirmannPeter Vollenweider
Dec 26, 2008·Clinical Therapeutics·Gabriel ChodickEhud Kokia
Mar 17, 2009·Lancet·Kornelia KotsevaUNKNOWN EUROASPIRE Study Group
Aug 25, 2009·Atherosclerosis·Mingfang LiBernard M Y Cheung
Dec 17, 2009·Current Medical Research and Opinion·Michel P HermansVedat Sansoy
Feb 20, 2010·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Andres JaussiRoger Darioli
Aug 13, 2010·The Annals of Pharmacotherapy·Devin M MannIan Kronish
Feb 8, 2011·Lancet·Farshad FarzadfarUNKNOWN Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Cholesterol)
Apr 1, 2011·European Journal of Preventive Cardiology·Anselm K GittUNKNOWN DYSIS Investigators
Apr 8, 2011·European Heart Journal·José R BanegasFernando Rodríguez-Artalejo
Oct 31, 2012·BMC Public Health·Kristin GustavsonEspen Røysamb
Mar 27, 2013·Archives of Cardiovascular Diseases·Vanina BongardJean Ferrières
May 7, 2013·The American Journal of Cardiology·Nathan D WongElizabeth Marrett
Jul 9, 2013·Swiss Medical Weekly·Alexander VonbankHeinz Drexel
Aug 3, 2013·European Heart Journal·Rajiv ChowdhuryOscar H Franco
Feb 19, 2015·PloS One·Julian P HalcoxFernando Rodriguez-Artalejo
Citations
Jan 28, 2017·Scientific Reports·Jing WuJunqi Niu
Jul 19, 2017·Advances in Therapy·Franck BoccaraPaul Valensi
Sep 21, 2016·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Assem ZhakupovaThorsten Hornemann
Jun 22, 2017·European Journal of Clinical Pharmacology·Nazanin AbolhassaniGérard Waeber
Nov 27, 2020·Nutrients·Michel BurnierMurielle Bochud
Mar 27, 2021·Scientific Reports·Julien CastioniPedro Marques-Vidal
Sep 15, 2021·Current Medical Research and Opinion·Vivencio BarriosAnastassia Anastassopoulou